Octagon is focused on developing targeted medicines for autoimmunity.  This new class of immunomodulators is activated by disease-related biology, ideal for episodic chronic disorders.  A lead program inhibits autoreactive B-cells that drive pemphigus, RA, and other autoimmune diseases.